MYCi975
CAS: 2289691-01-4
Ref. 3D-PRD69101
| 1mg | 164.00 € | ||
| 5mg | 450.00 € | ||
| 10mg | 641.00 € | ||
| 25mg | 1,078.00 € | ||
| 50mg | 1,724.00 € |
Product Information
MYCi975 is a drug candidate in the development of cancer-targeted therapies. MYCi975 binds to and inhibits the activity of the protein c-Myc, which plays a critical role in tumor formation and progression. This drug has been shown in vivo to inhibit tumor growth through apoptosis induction and cell cycle arrest. MYCi975 has also been shown to have anti-angiogenic effects and induce an immune response against tumors by stimulating T-cell production and proliferation. MYCi975 has shown promising results in vitro for pancreatic cancer, glioma, breast cancer, and other cancers that express the HER2 oncoprotein.
Chemical properties
Technical inquiry about: 3D-PRD69101 MYCi975
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
